Sumit Arora1,2,3, Mehra Haghi2,4, Paul M Young2, Michael Kappl3, Daniela Traini2, Sanyog Jain1. 1. a Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics , National Institute of Pharmaceutical Education and Research (NIPER) , Mohali , India. 2. b Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School , The University of Sydney , Sydney , Australia. 3. c Max Planck Institute for Polymer Research , Mainz , Germany. 4. d School of Pharmacy, Graduate School of Health , University of Technology , Sydney , Australia.
Abstract
OBJECTIVE: To develop and characterize a highly respirable dry powder inhalable formulation of voriconazole (VRZ). METHODS: Powders were prepared by spray drying aqueous/alcohol solutions. Formulations were characterized in terms of particle size, morphology, thermal, moisture responses and aerosolization performance. Optimized powder was deposited onto an air-interface Calu-3 model to assess their uptake across Calu-3 lung epithelia. Optimized formulation was evaluated for stability (drug content and aerosol performance) for 3 months. Additionally, Calu-3 cell viability, lung bioavailability and tissue distribution of optimized formulation were evaluated. RESULTS: Particle size and aerosol performance of dry powder containing 80% w/w VRZ and 20% w/w leucine was appropriate for inhalation therapy. Optimized formulation showed irregular morphology, crystalline nature, low moisture sensitivity and was stable for 3 months at room temperature. Leucine did not alter the transport kinetics of VRZ, as evaluated by air-interface Calu-3 model. Formulation was non-cytotoxic to pulmonary epithelial cells. Moreover, lung bioavailability and tissue distribution studies in murine model clearly showed that VRZ dry powder inhalable formulation has potential to enhance therapeutic efficacy at the pulmonary infection site whilst minimizing systemic exposure and related toxicity. CONCLUSION: This study supports the potential of inhaled dry powder VRZ for the treatment of fungal infections.
OBJECTIVE: To develop and characterize a highly respirable dry powder inhalable formulation of voriconazole (VRZ). METHODS: Powders were prepared by spray drying aqueous/alcohol solutions. Formulations were characterized in terms of particle size, morphology, thermal, moisture responses and aerosolization performance. Optimized powder was deposited onto an air-interface Calu-3 model to assess their uptake across Calu-3 lung epithelia. Optimized formulation was evaluated for stability (drug content and aerosol performance) for 3 months. Additionally, Calu-3 cell viability, lung bioavailability and tissue distribution of optimized formulation were evaluated. RESULTS: Particle size and aerosol performance of dry powder containing 80% w/w VRZ and 20% w/w leucine was appropriate for inhalation therapy. Optimized formulation showed irregular morphology, crystalline nature, low moisture sensitivity and was stable for 3 months at room temperature. Leucine did not alter the transport kinetics of VRZ, as evaluated by air-interface Calu-3 model. Formulation was non-cytotoxic to pulmonary epithelial cells. Moreover, lung bioavailability and tissue distribution studies in murine model clearly showed that VRZ dry powder inhalable formulation has potential to enhance therapeutic efficacy at the pulmonary infection site whilst minimizing systemic exposure and related toxicity. CONCLUSION: This study supports the potential of inhaled dry powder VRZ for the treatment of fungal infections.
Authors: Mellissa Gomez; Joseph McCollum; Hui Wang; Mani Ordoubadi; Chester Jar; Nicholas B Carrigy; David Barona; Isobel Tetreau; Michelle Archer; Alana Gerhardt; Chris Press; Christopher B Fox; Ryan M Kramer; Reinhard Vehring Journal: Int J Pharm Date: 2020-12-02 Impact factor: 5.875
Authors: Ranjot Kaur; Sarah R Dennison; Andrea J Burrow; Shivaprakash M Rudramurthy; Rajan Swami; Varun Gorki; O P Katare; Anupama Kaushik; Bhupinder Singh; Kamalinder K Singh Journal: J Nanobiotechnology Date: 2021-01-11 Impact factor: 10.435
Authors: Khaled Almansour; Iman M Alfagih; Alhassan H Aodah; Fawaz Alheibshy; Raisuddin Ali; Turki Al Hagbani; Mustafa M A Elsayed Journal: Pharmaceutics Date: 2021-12-30 Impact factor: 6.321